Lymph node-targeting nanovaccines for cancer immunotherapy

Wang, Qiu; Wang, Zhe; Sun, Xinxin; Jiang, Qikun; Sun, Bingjun; Zhang, He; Zhang, Shenwu; Luo, Cong; Sun, Jin

doi:10.1016/j.jconrel.2022.09.015

Cited by 27 publications

(25 citation statements)

References 181 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The application of nanotechnology in drug delivery marks an unparalleled opportunity to change the foreseeable future of the pharmaceutical and biotechnological industries. GO offers excellent opportunities for; vaccination, such as enhancing antigen uptake by DCs and stimulating antigen-specific humoral and cellular immunity, thereby achieving robust cancer immunotherapy ( Wang et al, 2022 ). GO has a typical two-dimensional crystal structure with a single atomic layer and oxygen functional groups.…”

Section: Discussionmentioning

confidence: 99%

“…Nanoparticles are minute particles that are typically <200 nm in diameter ( Chrastina et al, 2011 ) and exhibit unique properties, such as large surface-to-volume ratio, drug-loading compacity and tunable surface chemistry, confer many advantages in terms of vaccine delivery ( Xu et al, 2015 ). Recently, graphene oxide (GO) have been widely utilized as vehicles for drug delivery ( Zheng et al, 2018 ), biological sensors ( Xu et al, 2022 ) and have been applied successfully in photodynamic therapy ( Wei et al, 2016 ), cancer treatment ( Arya et al, 2018 ) and antibacterial therapy ( Wang et al, 2022 ). GO is derived from graphite via a variety of oxidation processes, the most common of which is the enhanced Hummers method ( Zhang et al, 2022 ).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Poria cocos polysaccharide—functionalized graphene oxide nanosheet induces efficient cancer immunotherapy in mice

Yang

Dong

et al. 2023

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Introduction: Tumor vaccines that induce robust humoral and cellular immune responses have attracted tremendous interest for cancer immunotherapy. Despite the tremendous potential of tumor vaccines as an effective approach for cancer treatment and prevention, a major challenge in achieving sustained antitumor immunity is inefficient antigen delivery to secondary lymphoid organs, even with adjuvant aid.Methods: Herein, we present antigen/adjuvant integrated nanocomplexes termed nsGO/PCP/OVA by employing graphene oxide nanosheet (nsGO) as antigen nanocarriers loaded with model antigen ovalbumin (OVA) and adjuvant, Poria cocos polysaccharides (PCP). We evaluated the efficacy of nsGO/PCP/OVA in activating antigen-specific humoral as well as cellular immune responses and consequent tumor prevention and rejection in vivo.Results: The optimally formed nsGO/PCP/OVA was approximately 120–150 nm in diameter with a uniform size distribution. Nanoparticles can be effectively engulfed by dendritic cells (DCs) through receptor-mediated endocytosis, induced the maturation of DCs and improved the delivery efficiency both in vitro and in vivo. The nsGO/PCP/OVA nanoparticles also induced a significant enhancement of OVA antigen-specific Th1 and Th2 immune responses in vivo. In addition, vaccination with nsGO/PCP/OVA not only significantly suppressed tumor growth in prophylactic treatments, but also achieved a therapeutic effect in inhibiting the growth of already-established tumors.Conclusion: Therefore, this potent nanovaccine platform with nanocarrier nsGO and PCP as adjuvants provides a promising strategy for boosting anti-tumor immunity for cancer immunotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Poria cocos polysaccharide—functionalized graphene oxide nanosheet induces efficient cancer immunotherapy in mice

Yang

Dong

et al. 2023

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

show abstract

“…[262][263][264][265][266][267] DCs, considered professional APCs, make up approximately 0.3% of the total cell population in the blood and can promote the proliferation and differentiation of CTLs. 268,269 Moreover, the quantity of DCs is strongly associated with the survival time of patients. 270,271 Therefore, DC-based vaccines are the most common vaccination approach for pediatric sarcomas, and patients who received a DC vaccine had a prolonged survival time compared with control patients.…”

Section: Conventional Immunotherapy For Osteosarcomamentioning

confidence: 99%

Managing the immune microenvironment of osteosarcoma: the outlook for osteosarcoma treatment

Tian

Cao

et al. 2023

Bone Res

View full text Add to dashboard Cite

Osteosarcoma, with poor survival after metastasis, is considered the most common primary bone cancer in adolescents. Notwithstanding the efforts of researchers, its five-year survival rate has only shown limited improvement, suggesting that existing therapeutic strategies are insufficient to meet clinical needs. Notably, immunotherapy has shown certain advantages over traditional tumor treatments in inhibiting metastasis. Therefore, managing the immune microenvironment in osteosarcoma can provide novel and valuable insight into the multifaceted mechanisms underlying the heterogeneity and progression of the disease. Additionally, given the advances in nanomedicine, there exist many advanced nanoplatforms for enhanced osteosarcoma immunotherapy with satisfactory physiochemical characteristics. Here, we review the classification, characteristics, and functions of the key components of the immune microenvironment in osteosarcoma. This review also emphasizes the application, progress, and prospects of osteosarcoma immunotherapy and discusses several nanomedicine-based options to enhance the efficiency of osteosarcoma treatment. Furthermore, we examine the disadvantages of standard treatments and present future perspectives for osteosarcoma immunotherapy.

show abstract

“…Monoclonal antibody and DCs’ natural carbohydrate ligands, such as mannose and glucose, have also been exploited for LN-targeted delivery . More details about LN-targeted drug vectors can be found in some excellent reviews recently published. ,, …”

Section: Immune Cell-based Drug Carriers For Cancer Immunotherapymentioning

confidence: 99%

“…130 More details about LN-targeted drug vectors can be found in some excellent reviews recently published. 119,130,131 Immune Cell-Derived Extracellular Vesicles as Drug Carriers. Although live cell-based drug carriers have brought hope to cancer immunotherapy, their biological stability and strict storage conditions limit their clinical application to some extent.…”

Section: Immune Cell-based Drug Carriers For Cancer Immunotherapymentioning

confidence: 99%

Harnessing Engineered Immune Cells and Bacteria as Drug Carriers for Cancer Immunotherapy

et al. 2023

View full text Add to dashboard Cite

Immunotherapy continues to be in the spotlight of oncology therapy research in the past few years and has been proven to be a promising option to modulate one's innate and adaptive immune systems for cancer treatment. However, the poor delivery efficiency of immune agents, potential off-target toxicity, and nonimmunogenic tumors significantly limit its effectiveness and extensive application. Recently, emerging biomaterial-based drug carriers, including but not limited to immune cells and bacteria, are expected to be potential candidates to break the dilemma of immunotherapy, with their excellent natures of intrinsic tumor tropism and immunomodulatory activity. More than that, the tiny vesicles and physiological components derived from them have similar functions with their source cells due to the inheritance of various surface signal molecules and proteins. Herein, we presented representative examples about the latest advances of biomaterial-based delivery systems employed in cancer immunotherapy, including immune cells, bacteria, and their derivatives. Simultaneously, opportunities and challenges of immune cells and bacteria-based carriers are discussed to provide reference for their future application in cancer immunotherapy.

show abstract

Lymph node-targeting nanovaccines for cancer immunotherapy

Cited by 27 publications

References 181 publications

Poria cocos polysaccharide—functionalized graphene oxide nanosheet induces efficient cancer immunotherapy in mice

Poria cocos polysaccharide—functionalized graphene oxide nanosheet induces efficient cancer immunotherapy in mice

Managing the immune microenvironment of osteosarcoma: the outlook for osteosarcoma treatment

Harnessing Engineered Immune Cells and Bacteria as Drug Carriers for Cancer Immunotherapy

Contact Info

Product

Resources

About